Tarek Mouhieddine

Dr. Tarek Mouhieddine

Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
orcid
Hematology/Oncology Fellow - Mount Sinai Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
OZOksana Zavidij
Oksana Zavidij
NHNicholas J. Haradhvala
Nicholas J. Haradhvala
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
RSRomanos Sklavenitis-Pistofidis
Romanos Sklavenitis-Pistofidis
SCSongjie Cai
Songjie Cai
IGIrene M. Ghobrial
Irene M. Ghobrial

12 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
ASAdam S. Sperling
Adam S. Sperling
RRRobert Redd
Robert Redd
JPJihye Park
Jihye Park
MLMatthew Leventhal
Matthew Leventhal
IGIrene M. Ghobrial
Irene M. Ghobrial
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) and is associated with adverse outcomes. Targeted sequencing of the stem cell product from 629 MM patients treated by ASCT at the Dana-Farber Cancer Institute (2003–2011) detects CHIP in 136/629 patients (21.6%). The most commonly mutated genes are DNMT3A, TET2, TP53, ASXL1 and PPM1D. Twenty-one from fifty-six patients (3.3%) receiving first-line IMiD maintenance develop a therapy-related myeloid neoplasm (TMN). However, regardless of CHIP status, the use of IMiD maintenance associates with improved PFS and OS. In those not receiving IMiD maintenance, CHIP is associated with decreased overall survival (OS) (HR:1.34, p = 0.02) and progression free survival (PFS) (HR:1.45, p < 0.001) due to an increase in MM progression.

22 September 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ANAnna S. Nam
Anna S. Nam
NDNeville Dusaj
Neville Dusaj
FIFranco Izzo
Franco Izzo
RMRekha Murali
Rekha Murali
RMRobert M. Myers
Robert M. Myers
DLDan A. Landau
Dan A. Landau

14 May 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YKYawara Kawano
Yawara Kawano
OZOksana Zavidij
Oksana Zavidij
JPJihye Park
Jihye Park
MMMichele Moschetta
Michele Moschetta
KKKatsutoshi Kokubun
Katsutoshi Kokubun
IGIrene M. Ghobrial
Irene M. Ghobrial
Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One of the major immunosuppressive mechanisms that is believed to play a role in myeloma progression is the expansion of regulatory T cells (Tregs). In this study, we demonstrate that myeloma cells drive Treg expansion and activation by secreting type 1 interferon (IFN). Blocking IFN α and β receptor 1 (IFNAR1) on Tregs significantly decreases both myeloma-associated Treg immunosuppressive function and myeloma progression. Using syngeneic transplantable murine myeloma models and bone marrow (BM) aspirates of MM patients, we found that Tregs were expanded and activated in the BM microenvironment at early stages of myeloma development. Selective depletion of Tregs led to a complete remission and prolonged survival in mice injected with myeloma cells. Further analysis of the interaction between myeloma cells and Tregs using gene sequencing and enrichment analysis uncovered a feedback loop, wherein myeloma-cell-secreted type 1 IFN induced proliferation and expansion of Tregs. By using IFNAR1-blocking antibody treatment and IFNAR1-knockout Tregs, we demonstrated a significant decrease in myeloma-associated Treg proliferation, which was associated with longer survival of myeloma-injected mice. Our results thus suggest that blocking type 1 IFN signaling represents a potential strategy to target immunosuppressive Treg function in MM.

1 June 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EAElio Adib
Elio Adib
Amin NassarAmin Nassar
Amin Nassar
EAElie W. Akl
Elie W. Akl
SASarah Abou Alaiwi
Sarah Abou Alaiwi
PNPier Vitale Nuzzo
Pier Vitale Nuzzo
DKDavid J. Kwiatkowski
David J. Kwiatkowski
Purpose: Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GA) and response to ICIs. Herein, we examined the impact of loss-of-function CDKN2A alterations on response and survival in patients treated with ICIs. Experimental Design: We studied the association between loss-of-function CDKN2A alterations and the response to ICIs in two independent cohorts of six different cancer types. Seven hundred and eighty-nine patients treated at Dana-Farber Cancer Institute (DFCI; Boston, MA) and 1,250 patients treated at Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY) were included in the final analysis. Patients' tumors were sequenced using Oncopanel or MSK-IMPACT. RNA sequencing data from The Cancer Genome Atlas and IMvigor210 were used to investigate differences in the tumor microenvironment. Results: In the DFCI cohort, CDKN2A GAs were associated with poor response and survival in patients with urothelial carcinoma treated with ICIs, but not those treated with platinum-based therapy. Similarly, CDKN2A GAs were associated with worse outcomes in the MSKCC urothelial carcinoma cohort treated with ICIs. There was no association of CDKN2A status with ICI treatment outcome in five other cancers: esophagogastric, head and neck, non–small cell lung, renal cell carcinoma, and melanoma. Immuno-inflammatory pathways were significantly reduced in expression in CDKN2A-altered tumors. Conclusions: Our data show that CDKN2A GAs were associated with reduced benefit from ICI therapy in urothelial carcinoma as well as changes in the tumor–immune microenvironment.

16 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
OOOliver Van Oekelen
Oliver Van Oekelen
KNKarthik Nath
Karthik Nath
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
TFTasmin Farzana
Tasmin Farzana
AAAdolfo Aleman
Adolfo Aleman
SPSamir Parekh
Samir Parekh
B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration–approved BCMA-directed CAR T products. However, despite high initial response rates, most patients eventually relapse. The outcomes of patients with disease recurrence after BCMA-directed CAR T have not been comprehensively studied, and such an analysis would help define optimal treatment strategies. We analyzed the salvage treatments and outcomes of 79 patients with multiple myeloma from two academic institutions, who had progression of disease after treatment with BCMA-directed CAR T. A total of 237 post–CAR T salvage treatment lines were used, and patients received a median of 2 (range, 1-10) treatment lines. The median overall survival from the date of relapse post-CAR T therapy was 17.9 months (95% confidence interval [CI], 14.0 non-estimable). The overall response rate to the first salvage regimen was 43.4%, with a median progression-free survival of 3.5 months (CI, 2.5-4.6). Thirty-five patients (44.3%) received a T-cell–engaging therapy (bispecific antibody or subsequent CAR T) as salvage treatment. The overall survival in patients who received subsequent T-cell–engaging therapy was not reached after a median follow up of 21.3 months. Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy. T-cell–engaging therapies appear to maintain pronounced clinical activity in this setting.